Floatz logo

kqb198

KRAS G12C Mutation

Kumquat Biosciences Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the KRAS G12C Mutation cohort.

Asset / SponsorPhaseRating
Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2B
Abemaciclib
Alliance for Clinical Trials in Oncology
Phase 2CCC
Entrectinib
Alliance for Clinical Trials in Oncology
Phase 2CCC
Sotorasib
Federation Francophone de Cancerologie Digestive
Phase 2CCC
FLUOROURACILUM
Federation Francophone de Cancerologie Digestive
Phase 2CCC

View all 12 →

Same molecule, other indications

kqb198 is also rated in:

KRAS G12S MutationDormant
CC
Indicative ·
43 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
41 / 100
View asset →
Solid Tumor MalignanciesDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →